phase readout
saveNCT02489318: A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
ACTIVE_NOT_RECRUITINGupdated 2mo ago
community read0 votes
Sponsor: Aragon Pharmaceuticals, Inc.. Phase: PHASE3. Conditions: Prostate Cancer
view source ↗
comments(0)
5-min edit window · permanent after that